![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Details:
The funding will support the continued development of a promising medical countermeasure for nerve agents that contain a stable, fixed-dose combination formulation of atropine and scopolamine.
Lead Product(s): Atropine Sulfate,Scopolamine
Therapeutic Area: Pharmacology/Toxicology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: U.S. Defense Department
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding December 06, 2022